Sino Biopharmaceutical secures key breast cancer indication

Sino Biopharmaceutical announced its subsidiary's Culmerciclib Capsule (TQB3616) has had its new indication application accepted by China's CDE. This application is for the first-line treatment of previously untreated HR+/HER2- advanced or metastatic breast cancer, in combination with fulvestrant.

The Phase III clinical study met its primary endpoint. This acceptance marks a significant step, confirming the strong potential of this combination therapy for various stages of advanced breast cancer.